Figure 5.

The local dose of doxorubicin reshapes tumor immune-interacting marker expression in vivo. (a) Experimental timeline and treatment groups. Mice were inoculated with B16-mCherry tumors, treated 12 days later, and tumors were analyzed 3 days after treatment. Doxorubicin was delivered locally delivered from a cryogel at two doses: 7.5 mg/kg (high) or 1 mg/kg (low), or intraperitoneally in a bolus injection at 7.5 mg/kg. Blank cryogels served as controls. (b) Representative flow cytometry histograms of calreticulin on mCherry⁺ tumor cells. (c) Representative flow cytometry plots of PD-L2 on mCherry⁺ tumor cells. Quantification of expression of MHC-I (d), PD-L1 (e), PD-L2 (f), CD47 (g), Fas (h), and calreticulin (i) on mCherry⁺ tumor cells.